Clinical Trials · NCT03819790

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

CompletedPhase 4Lixisenatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
LMC Diabetes & Endocrinology Ltd.
Enrollment
119
Start date
Oct 2018
Locations
3 sites, Canada
Primary endpoint
Time in range at week 13
View Lixisenatide compound reference